Pacira Pharmaceuticals Continues to Build Out Robust Commercial Leadership Team
October 20 2016 - 7:30AM
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced the
appointment of two key individuals who will assume leadership roles
within the company’s commercial organization. Thomas Sluby has been
named Vice President, Sales and Matthew Lehmann has been appointed
Vice President, Marketing – Emerging Therapies; both individuals
will report to Robert Weiland, Chief Commercial Officer.
Mr. Sluby is responsible for the coordination, management, and
leadership of the Pacira sales organization, overseeing all aspects
of sales execution and customer relations. Mr. Sluby will work
closely with the commercial team on the development and
implementation of sales and product strategies for EXPAREL®
(bupivacaine liposome injectable suspension).
Mr. Lehmann will be responsible for the development,
implementation, and execution of market strategies and tactics,
initially focusing on the EXPAREL nerve block launch subsequent to
approval. Pacira is currently enrolling two Phase 3 studies in
lower and upper extremity nerve blocks. Mr. Lehmann will also
oversee development of the marketing and sales approaches for
future EXPAREL indications and the launch of additional products in
the Pacira pipeline.
“We are excited to add Tom and Matt, two seasoned pharmaceutical
executives with long track records of success building and
executing on comprehensive commercialization strategies, to the
Pacira leadership team,” said James Scibetta, President of Pacira.
“We expect these key additions to the commercial side of our
business to significantly contribute to the success of EXPAREL
infiltration in the acute care marketplace, while positioning the
company for future success, beginning with the planned launch of
EXPAREL for nerve block.”
Mr. Sluby joins Pacira from inVentiv Health, where he served as
National Business Director, responsible for overseeing the sales
and performance management of three national sales forces. Prior to
this position, Mr. Sluby served as Senior Vice President of Global
Client Relations for Taconic BioSciences, where he led a global
sales and marketing team. Mr. Sluby also held several
management roles during a 15-year period at Eisai, Inc., including
National Sales Director of Neurology, Gastroenterology and
LTC/Hospital, where he drove revenue in therapeutic areas ranging
from Alzheimer’s and acid reflux to epilepsy and
low-molecular-weight heparin.
Prior to Pacira, Mr. Lehmann held various executive positions
during a 21-year career at AstraZeneca, most recently as Head of
the Neuroscience Franchise where he was responsible for the
successful market build-out and launch of Movantik®. Mr. Lehmann
also served as Executive Director, Commercial Leader for Seroquel
XR® and Movantik, overseeing all commercial decisions covering
healthcare professional, consumer, and managed markets marketing,
as well as government affairs and pricing work.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty
pharmaceutical company focused on the clinical and commercial
development of new products that meet the needs of acute care
practitioners and their patients. The company’s flagship product,
EXPAREL® (bupivacaine liposome injectable suspension), indicated
for single-dose infiltration into the surgical site to produce
postsurgical analgesia, was commercially launched in the United
States in April 2012. EXPAREL and two other products have
successfully utilized DepoFoam®, a unique and proprietary product
delivery technology that encapsulates drugs without altering their
molecular structure, and releases them over a desired period of
time. Additional information about Pacira is available at
www.pacira.com.
About EXPAREL®
EXPAREL (bupivacaine liposome injectable suspension) is
currently indicated for single-dose infiltration into the surgical
site to produce postsurgical analgesia. The product combines
bupivacaine with DepoFoam®, a proven product delivery technology
that delivers medication over a desired time period. EXPAREL
represents the first and only multivesicular liposome local
anesthetic that can be utilized in the peri- or postsurgical
setting. By utilizing the DepoFoam platform, a single dose of
EXPAREL delivers bupivacaine over time, providing significant
reductions in cumulative pain score with up to a 45 percent
decrease in opioid consumption; the clinical benefit of the opioid
reduction was not demonstrated. Additional information is available
at www.EXPAREL.com.
Forward Looking Statements
Any statements in this press release about our future
expectations, plans, outlook and prospects, and other statements
containing the words “believes,” “anticipates,” “plans,”
“estimates,” “expects,” “intends,” “may” and similar
expressions, constitute forward-looking statements within the
meaning of The Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by such
forward-looking statements as a result of various important
factors, including risks relating to: the success of our sales and
manufacturing efforts in support of the commercialization of
EXPAREL; the rate and degree of market acceptance of EXPAREL; the
size and growth of the potential markets for EXPAREL and our
ability to serve those markets; our plans to expand the use of
EXPAREL to additional indications and opportunities, and the timing
and success of any related clinical trials; the related timing and
success of United States Food and Drug Administration supplemental
New Drug Applications; the outcome of the U.S. Department of
Justice inquiry; our plans to evaluate, develop and pursue
additional DepoFoam-based product candidates; clinical studies in
support of an existing or potential DepoFoam-based product; our
plans to continue to manufacture and provide support services for
our commercial partners who have licensed DepoCyt(e); our
commercialization and marketing capabilities; our and Patheon UK
Limited’s ability to successfully and timely construct dedicated
EXPAREL manufacturing suites; and other factors discussed in the
“Risk Factors” of our most recent Annual Report on Form 10-K for
the fiscal year ended December 31, 2015 and in other filings that
we periodically make with the SEC. In addition, the forward-looking
statements included in this press release represent our views as of
the date of this press release. Important factors could cause our
actual results to differ materially from those indicated or implied
by forward-looking statements, and as such we anticipate that
subsequent events and developments will cause our views to change.
However, while we may elect to update these forward-looking
statements at some point in the future, we specifically disclaim
any obligation to do so. These forward-looking statements should
not be relied upon as representing our views as of any date
subsequent to the date of this press release.
Company Contact:
Pacira Pharmaceuticals, Inc.
Jessica Cho, (973) 254-3574
jessica.cho@pacira.com
Media Contact:
Coyne Public Relations
Alyssa Schneider, (973) 588-2270
aschneider@coynepr.com
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Pacira BioSciences (NASDAQ:PCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024